Litigation Details for AstraZeneca AB v. Watson Laboratories Inc. (D. Del. 2014)

AstraZeneca AB v. Watson Laboratories Inc. (D. Del. 2014)

Docket		Date Filed	2014-05-23
Court	District Court, D. Delaware	Date Terminated	2015-04-16
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Defendant	Referred To
Patents	7,951,400; RE44,186
Link to Docket	External link to docket

Details for AstraZeneca AB v. Watson Laboratories Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-05-23	1		product, prior to expiration of U.S. Patent No. 7,951,400 (“the ’400 patent”). ME1 17953993v.2 Case … This is an action for patent infringement arising under the patent laws of the United States, … PATENT-IN-SUIT 17. On May 31, 2011, the U.S. Patent and Trademark Office…copy of the ’400 patent is attached hereto as Exhibit A. The claims of the ’400 patent are valid and enforceable…includes ONGLYZA® together with the ’400 patent and U.S. Patent No. RE44,186, which covers the composition	External link to document
2014-09-23	16		than April 10, 2014. Date of Expiration of Patent: 7,951,400 (November 30, 2028).Thirty Month Stay Deadline… Amended Supplemental information for patent cases involving an Abbreviated New Drug Application…2014 16 April 2015 1:14-cv-00666 830 Patent Defendant District Court, D. Delaware	External link to document
2014-05-23	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,951,400. (rwc) (Entered: 05…2014 16 April 2015 1:14-cv-00666 830 Patent Defendant District Court, D.	External link to document